Today: 21 July 2026
Browse Category

NYSE:KVUE 14 October 2025 - 9 November 2025

For live price, interactive charts, financials and the latest market data, visit Google Finance.
P&G Earnings Smash Estimates – Beauty Boom and Razors Fly Off Shelves in Q1

PG Stock Today: What to Know Before the Bell on November 10, 2025 (Earnings, Dividend, Tariffs, and Sector M&A)

Summary• PG closed Friday, November 7 at $146.98, sitting near the low end of its 52‑week range. Market cap is about $343B. StockAnalysis+1• P&G’s latest quarter delivered net sales of $22.4B, organic sales +2%, and core EPS of $1.99. FY26 guidance: all‑in sales +1% to +5%, core EPS $6.83–$7.09; management now bakes in ~$400M after‑tax tariff headwind and ~$100M commodity headwind, offset by an FX tailwind of ~$300M. PG Investor• Dividend watch: the next $1.0568 per‑share payout lands Monday, November 17. Trailing forward yield is ~2.9% at current prices. PG Investor+1• Leadership transition: COO Shailesh Jejurikar becomes CEO on Jan. 1, 2026; Jon Moeller shifts to executive chairman—operational continuity is expected but investors will listen for transition color. us.pg.com• Legal overhang to watch: a federal judge just allowed a lawsuit over Kid’s Crest packaging to proceed. While damages, if any, are unclear, headlines can sway sentiment in the near term. Reuters• Sector backdrop: Kimberly‑Clark’s bid to buy Kenvue for >$40B reshapes staples, with implications for categories where P&G competes. Reuters+1• Macro this week: October CPI hits Thursday, Nov. 13. Into Monday, the 10‑year Treasury last printed ~4.11% and DXY hovered near 99.6—levels that often influence defensives’ multiples. Bureau of Labor
9 November 2025
····
Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue Inc. is a leading consumer health company formed from Johnson & Johnson’s storied consumer products division. The name “Kenvue” combines “ken” and “vue”, reflecting a vision of insight-driven careen.wikipedia.org. As a spin-off, Kenvue took over J&J’s well-known retail brands, ranging from over-the-counter medicines to skincare and baby care. Today its portfolio spans three segmentsinvesting.com:
4 November 2025
···
Kimberly-Clark’s $40 Billion Gamble Sends KMB Stock Plunging – What’s Next for This Dividend King?

Kimberly-Clark’s $40 Billion Gamble Sends KMB Stock Plunging – What’s Next for This Dividend King?

As of November 4, 2025, Kimberly-Clark’s stock is trading around $102 per share, near its 52-week low. The current price reflects a dramatic sell-off that occurred on Monday, Nov 3, when KMB plunged from the high-$110s into the low $100s in a single sessionstockanalysis.com. Specifically, the stock collapsed -14.57% on Nov 3 to close at $102.27stockanalysis.com – an unusually large one-day move for a traditionally stable consumer staples stock. That wipeout followed an already soft October for the shares, which had hovered around $119-$120 in the prior weekchartmill.comchartmill.com.
4 November 2025
··
Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kenvue’s stock soared on the buyout news, delivering a sharp one-day gain. As of midday Nov. 3, KVUE traded around $17–$18, up roughly 18–20% intraday Reuters. Prior to the announcement, the stock had closed at $14.37 on Oct. 31 Stockanalysis, near its 52-week low of ~$14.02 Reuters Reuters. The takeover premium immediately boosted KVUE, though the share price remained a bit below the offer value – typical in cash/stock mergers as arbitragers factor in execution timing and Kimberly-Clark’s own stock movement Reuters. Overall, the market reaction reflected optimism for Kenvue shareholders locking in a significant premium after a prolonged slump. By contrast, Kimberly-Clark’s stock declined on fears of deal dilution and debt load, since KMB will partly fund the cash portion via new debt and a business unit sale Prnewswire.
3 November 2025
····
Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue’s shares collapsed to an all-time low since their mid-2023 IPO, closing around $14 after Thursday’s 13.2% plunge stocktwits.com. The one-day drop – Kenvue’s worst on record – was triggered by headline risks that blindsided investors. By early Friday, October 17, the stock stabilized slightly after the rout stocktwits.com. Still, at roughly 40% below its IPO price, the Johnson & Johnson spinoff has seen its market capitalization shrink to about $30–31 billion reuters.com.
17 October 2025
···
Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

Kenvue’s stock has been volatile. On Oct 16, 2025 it closed around $15.46, marking a fresh 52-week lowinvesting.com. Over the prior week the shares had slid ~13%, partly driven by jitters over UK talc lawsuits and Trump-era Tylenol claims. Investors bid on options, with call volume surging 52% on Oct 13marketbeat.com, even as the stock dipped 2.9% that day to $16.17marketbeat.com. Year-to-date KVUE is roughly flat to down modestly, but it lags the broader market. For context, the S&P 500 was nearly unchanged while Kenvue was down ~5% on Oct 16. A longer view shows KVUE rose after its 2023 IPO but has struggled through 2024–2025 amid headwinds.
16 October 2025
·
J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

Johnson & Johnson, a healthcare conglomerate, historically consisted of consumer health, pharmaceutical, and medical technology divisions. In 2023 J&J spun off its consumer products into a new public company, Kenvue. Now it is moving a second business out: the orthopedics arm of its MedTech division. The spin-off means J&J will remain focused on pharmaceuticals and higher-growth medical devices, while DePuy Synthes inherits the hip/knee/shoulder implant and surgical tools business reuters.com jnj.com. Spin-offs are commonly used to allow each entity to pursue tailored strategies; for J&J this means the legacy orthopedics line can seek dedicated investors and potentially invest more aggressively in its own R&D, while J&J can reallocate capital to areas like biotech drugs and cutting-edge devices.
14 October 2025
·
1 2 3
Go toTop